Compositions and methods for treating age-related diabetes and related disorders
Sagar P. Bapat, La Jolla, CA (US); Ye Zheng, La Jolla, CA (US); Ronald Evans, La Jolla, CA (US); Michael Downes, La Jolla, CA (US); Annette R. Atkins, La Jolla, CA (US); and Ruth T. Yu, La Jolla, CA (US)
Assigned to Salk Institute for Biological Studies, La Jolla, CA (US)
Filed by Salk Institute for Biological Studies, La Jolla, CA (US)
Filed on Jul. 19, 2022, as Appl. No. 17/813,383.
Application 17/813,383 is a division of application No. 16/702,870, filed on Dec. 4, 2019, granted, now 11,428,697.
Application 16/702,870 is a division of application No. 15/544,385, granted, now 10,539,572, issued on Jan. 21, 2020, previously published as PCT/US2016/013004, filed on Jan. 12, 2016.
Claims priority of provisional application 62/154,652, filed on Apr. 29, 2015.
Claims priority of provisional application 62/110,349, filed on Jan. 30, 2015.
Prior Publication US 2023/0078590 A1, Mar. 16, 2023
1. A method of reducing insulin resistance in a subject who has insulin resistance or who is identified as being at risk of developing insulin resistance, the method comprising administering to a subject in need thereof an anti-ST2 antibody or an antigen binding fragment thereof, wherein prior to said anti-ST2 antibody administration, the subject is identified as having insulin resistance or as being at risk of developing insulin resistance by measuring in a sample obtained from the subject an increase in an ST2 polypeptide or polynucleotide expression in a fat-resident regulatory T (fTreg) cell or an increase in the number of fTreg cells compared with a normal control.